GlaxoSmithKline Pharmaceuticals
- Market cap
- ₹ 40,801 Cr.
- P/E
- 40.1x
- P/B
- 18.18x
- 52-week range
- 2,088.1 – 3,120.7
- ROE
- 46%
- ROCE
- 61%
- Dividend yield
- 2.3%
- Debt / equity
- 0.01
- Sector
- Pharmaceuticals & Biotechnology
- Industry
- Pharmaceuticals
- Listed on
- NSE, BSE
About
GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Pharmaceuticals: 221 companies →GlaxoSmithKline Pharmaceuticals against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)40.1 against a typical 34.3: pricier than most peers (1st = cheapest).129th of 220
- Sales growth+16.5% against a typical +15.6% from a year earlier.95th of 197
- Profit growth+15.6% against a typical +18.9% from a year earlier.91st of 160
- Share price, 3 months−4.8% against a typical −0.5%.122nd of 200
- Size₹ 40,801 Cr. market value against a typical ₹ 507.7 Cr. (1st = largest).17th of 199
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 3 Nov 2026Upcoming | Financial Results | To consider and approve the financial results for the period ended September 30, 2026 |
| 3 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 13 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 9 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 6 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 1 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
| 13 May 2025 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2025 and dividend |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 957 | 805 | 930 | 815 | 1,011 | 949 | 974 | 805 | 980 | 1,041 | 995 | 938 |
| Expenses | 668 | 587 | 673 | 584 | 689 | 658 | 641 | 554 | 644 | 670 | 644 | 643 |
| Operating Profit | 289 | 218 | 257 | 231 | 322 | 292 | 333 | 251 | 336 | 371 | 351 | 296 |
| OPM % | 30% | 27% | 28% | 28% | 32% | 31% | 34% | 31% | 34% | 36% | 35% | 31% |
| Other Income | 28 | −135 | 32 | 36 | 39 | 35 | 41 | 44 | 36 | 50 | 36 | 44 |
| Interest | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 |
| Depreciation | 18 | 17 | 18 | 16 | 17 | 19 | 15 | 16 | 17 | 20 | 13 | 16 |
| Profit before tax | 299 | 65 | 271 | 249 | 344 | 308 | 359 | 279 | 354 | 400 | 373 | 322 |
| Tax % | 27% | 30% | 28% | 27% | 27% | 25% | 27% | 27% | 27% | 26% | 26% | 26% |
| Net Profit | 218 | 46 | 194 | 182 | 252 | 230 | 263 | 205 | 257 | 296 | 278 | 237 |
| EPS in Rs | 12.84 | 2.7 | 11.48 | 10.76 | 14.91 | 13.57 | 15.52 | 12.1 | 15.2 | 17.45 | 16.4 | 14 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 3%
- 5 Years
- 5%
- 3 Years
- 6%
- TTM
- 6%
- 10 Years
- 10%
- 5 Years
- 15%
- 3 Years
- 18%
- TTM
- 11%
- 10 Years
- 7%
- 5 Years
- 14%
- 3 Years
- 29%
- TTM
- —
- 10 Years
- 33%
- 5 Years
- 48%
- 3 Years
- 43%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| GlaxoSmithKline Pharmaceuticals | ₹ 2,500.00 | ₹ 40,801 Cr. | 40.1x | 18.2x | 46% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 38.4x | 5.6x | 14.2% | 19.1% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 73.3x | 11.5x | 16.2% | 24.3% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 72.7x | 19.2x | 27.1% | 15.3% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 27.6x | 3.3x | 11.8% | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.2x | 4.2x | 19.7% | 18.5% |
Management
- Ronojit Biswas
- Chief Financial Officer, Whole-Time Director
- Carson Dalton
- Executive Vice President - Communications and Government Affairs
- Rishikesh Jaiwant
- Executive Vice President - Supply Chain Operations
- Shalini Menon
- Executive Vice President - Medical Affairs
- Amit Pandey
- Executive Vice President - Legal
- Vibhuti Gupta
- Vice President - Commercial Operations and Strategy
- Sharmishta Mitra
- Vice President - Paediatric Vaccines
- Omkar Parnandiwar
- Vice President - Adult Vaccines
Prices are delayed and for information only. Nothing on this page is investment advice.